Analysts Set Expectations for GeoVax Labs FY2029 Earnings

GeoVax Labs, Inc. (NASDAQ:GOVX) – Investment analysts at Roth Capital issued their FY2029 EPS estimates for shares of GeoVax Labs in a research note issued on Friday, March 28th. Roth Capital analyst J. Aschoff expects that the company will post earnings of $12.20 per share for the year. The consensus estimate for GeoVax Labs’ current full-year earnings is ($4.49) per share.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.49. The firm had revenue of $3.00 million during the quarter, compared to the consensus estimate of $2.38 million.

Separately, D. Boral Capital reissued a “buy” rating and set a $18.00 target price on shares of GeoVax Labs in a research note on Friday. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $14.20.

GeoVax Labs Stock Down 4.5 %

Shares of GeoVax Labs stock opened at $1.06 on Monday. The company has a market capitalization of $10.00 million, a price-to-earnings ratio of -0.19 and a beta of 3.06. The stock’s 50-day simple moving average is $1.64 and its 200-day simple moving average is $2.11. GeoVax Labs has a 52 week low of $1.06 and a 52 week high of $11.18.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in GOVX. Citadel Advisors LLC bought a new position in GeoVax Labs during the fourth quarter valued at approximately $104,000. Northern Trust Corp bought a new stake in GeoVax Labs in the 4th quarter worth approximately $29,000. Geode Capital Management LLC raised its holdings in shares of GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after acquiring an additional 33,440 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of GeoVax Labs during the 3rd quarter worth approximately $97,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.